Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes

被引:20
|
作者
Laugier-Robiolle, Stephanie [1 ,2 ]
Verges, Bruno [3 ]
Le Bras, Maelle [4 ]
Gand, Elise [1 ,2 ]
Bouillet, Benjamin [3 ]
Saulnier, Pierre-Jean [5 ]
Le May, Cedric [6 ]
Pichelin, Matthieu [7 ]
Marechaud, Richard [1 ,2 ]
Petit, Jean-Michel [3 ]
Hadjadj, Samy [1 ,2 ,5 ,8 ]
Cariou, Bertrand [7 ]
机构
[1] CHU Poitiers, Endocrinol Diabetol, Poitiers, France
[2] CHU Poitiers, CIC1402, Poitiers, France
[3] Univ Bourgogne, Dept Endocrinol, INSERM, CRI 866,CHU Dijon, Dijon, France
[4] CHU Nantes, Inst Thorax, Dept Endocrinol, Nantes, France
[5] INSERM, CIC1402, Poitiers, France
[6] Univ Nantes, Inst Thorax, INSERM, CNRS, Nantes, France
[7] Univ Nantes, CHU Nantes, Dept Endocrinol, Inst Thorax,INSERM,CNRS, Nantes, France
[8] Univ Poitiers, UFR Med Pharm, Poitiers, France
来源
DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 03期
关键词
dyslipidaemia; lipid-lowering therapy; type; 1; diabetes; SUBTILISIN/KEXIN TYPE 9; CARDIOVASCULAR-DISEASE; ASSOCIATION; EXPRESSION; INSULIN;
D O I
10.1111/dom.12819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a critical regulator of LDL cholesterol metabolism. Little is known, however, about the regulation of PCSK9 in patients with type 1 diabetes (T1D). In the present study, we aimed to determine the relationship between circulating PCSK9 and metabolic variables in T1D. Plasma PCSK9 levels were measured in 195 people with T1D (mean age 38.8 years, mean diabetes duration 17.2 years, mean glycated haemoglobin [HbA1c] 8.3%), who were free of any lipid-lowering agent. Plasma PCSK9 was positively correlated with LDL cholesterol (P =.0007), triglycerides (P =.004), apolipoprotein B (P =.005), HbA1c (P =.003), systolic (P =.003) and diastolic (P =.001) blood pressure and body mass index (0.02). In multivariate analysis, PCSK9 concentration was independently associated with HbA1c (P =.02) and LDL cholesterol (P =.03). After classifying patients according to HbA1c tertile, the correlation between PCSK9 and LDL cholesterol was only observed in the highest tertile (P =.0006; Rho = 0.43), whereas no correlation was found in the lowest and intermediate tertiles. This study suggests that good glycaemic control abolishes the positive relationship between PCSK9 and LDL cholesterol in patients with T1D; however, the underlying molecular mechanisms remain to be established.
引用
收藏
页码:448 / 451
页数:4
相关论文
共 50 条
  • [21] Antibodies to PCSK9 A Superior Way to Lower LDL Cholesterol?
    Maxwell, Kara N.
    Breslow, Jan L.
    CIRCULATION RESEARCH, 2012, 111 (03) : 274 - 277
  • [22] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol REPLY
    Swergold, Gary D.
    Stein, Evan A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25): : 2426 - 2426
  • [23] Potential of PCSK9 as a new target for the management of LDL cholesterol
    Mombelli, Guiliana
    Castelnuovo, Samuela
    Pavanello, Chiara
    RESEARCH REPORTS IN CLINICAL CARDIOLOGY, 2015, 6 : 73 - 86
  • [24] Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
    Safarova, Maya
    Bimal, Tia
    Soffer, Daniel E.
    Hirsh, Benjamin
    Shapiro, Michael D.
    Mintz, Guy
    Cha, Agnes
    Gianos, Eugenia
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 19
  • [25] Therapies That Target PCSK9 Effective at Reducing LDL Cholesterol
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (20): : 2054 - 2054
  • [26] TRIAL WATCH PCSK9 antibody reduces LDL cholesterol
    Crunkhorn, Sarah
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (01) : 11 - 11
  • [27] PCSK9 Inhibitors The Magic Bullet for LDL Cholesterol Reduction?
    Richter, Kurt
    Barthel, Andreas
    Bornstein, Stefan R.
    El-Armouche, Ali
    Wagner, Michael
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (12) : 863 - U181
  • [28] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [29] PCSK9 and LDL cholesterol: unravelling the target to design the bullet
    Costet, Philippe
    Krempf, Michel
    Cariou, Bertrand
    TRENDS IN BIOCHEMICAL SCIENCES, 2008, 33 (09) : 426 - 434
  • [30] Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes
    Verges, Bruno
    Duvillard, Laurence
    Brindisi, Marie Claude
    Gautier, Emmanuel
    Krempf, Michel
    Costet, Philippe
    Cariou, Bertrand
    ATHEROSCLEROSIS, 2011, 219 (01) : 342 - 348